This article is more than 5 years old. Information may no longer be current.

VIDEO: Trial of embolic protection during TAVR confirms need for further study

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WASHINGTON — In this video, Patrick T. O’Gara, MD, MACC, past president of the American College of Cardiology and director of clinical cardiology and executive medical director, Shapiro Cardiovascular Center, Brigham and Women’s Hospital, discusses embolic protection during transcatheter aortic valve replacement to reduce stroke risk.

“I think any randomized trial that is designed to answer a question as to whether we can reduce that incidence is of very high importance to the cardiology and cardiac surgical community,” O’Gara said.

The SENTINEL study did not show a significant difference in neurocognitive function or brain lesion volume with embolic protection device use. O’Gara said he is disappointed by the trial results, but sees an opportunity to explore other strategies to reduce stroke.

“I do think that although that it might be advertised as a negative trial, it adds to the body of information and validates the need for us to continue to push the envelope of investigation so we can help these patients,” he said.